[en] The diagnosis of Duchenne muscular dystrophy (DMD) is significant at any stage, however an early diagnosis in a presymptomatic or very early phase of DMD, offers unique opportunities and challenges for families and health care providers. Currently, there is limited evidence as to the optimal models of care during this stage of the condition.. To address this, in 2023, Treat-NMD facilitated the Early Diagnosis for DMD project; bringing together 42 experts from across Europe, the US and Australasia, including health care professionals, researchers, and people with lived experience to discuss the complexities of an early or newborn diagnosis of DMD, and provide recommendations regarding approaches to multidisciplinary care. A series of virtual meetings followed by a hybrid workshop resulted in broad recommendations to support clinicians in caring for children and families following an early diagnosis of DMD. The workshop did not define a cut-off for early diagnosis, however much of the discussion focused on diagnoses that occurred prior to 2 years. There is recognition that boys may first present with non-motor symptoms, such as speech delay or neurodevelopmental issues that are secondary to their dystrophinopathy, and therefore this report refers reflects that infants with DMD may be presymptomatic or early symptomatic.
Disciplines :
Pediatrics
Author, co-author :
Lorentzos, M; Department of Neurology and Neurosurgery, The Sydney Children's Hospitals Network, Sydney, New South Wales, Australia, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia. Electronic address: Michelle.lorentzos@health.nsw.gov.au
Parsons, J A; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
Jones, K J; Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Department of Clinical Genetics, The Sydney Children's Hospitals Network,, Sydney, New South Wales, Australia
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques
Treat NMD Early Diagnosis Workshop Participants
Language :
English
Title :
Early diagnosis of Duchenne muscular dystrophy - A Treat-NMD international workshop.
Saad, F.A., Siciliano, G., Angelini, C., Advances in dystrophinopathy diagnosis and therapy. Biomolecules, 13(9), 2023.
Bombard, Y., Miller, F.A., Hayeems, R.Z., Avard, D., Knoppers, B.M., Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. EJHG 18:7 (2010), 751–760.
Ke, Q., Zhao, Z.Y., Mendell, J.R., Baker, M., Wiley, V., Kwon, J.M., et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World J Pediatr 15:3 (2019), 219–225.
Mendell, J.R., Shilling, C., Leslie, N.D., Flanigan, K.M., al-Dahhak, R., Gastier-Foster, J., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:3 (2012), 304–313.
Tavakoli, N.P., Gruber, D., Armstrong, N., Chung, W.K., Maloney, B., Park, S., et al. Newborn screening for Duchenne muscular dystrophy: a two-year pilot study. Ann Clin Transl Neurol 10:8 (2023), 1383–1396.
Chien, Y.H., Lee, N.C., Weng, W.C., Chen, L.C., Huang, Y.H., Wu, C.S., et al. Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan. Neurol Sci 43:7 (2022), 4563–4566.
Jia, X., Jiang, X., Huang, Y., A pilot study of newborn screening for Duchenne muscular dystrophy in Guangzhou. Heliyon, 8(10), 2022, e11071.
Beckmann, R., Scheuerbrandt, G., Screening for elevated creatine kinase activities for the early diagnosis of Duchenne muscular dystrophy. Fortschr Med 97:39 (1979), 1733–1736.
Hutton, E.M., Thompson, M.W., Carrier detection and genetic counselling in Duchenne muscular dystrophy: a follow-up study. Can Med Assoc J 115:8 (1976), 749–752.
Birnkrant, D.J., Bushby, K., Bann, C.M., Apkon, S.D., Blackwell, A., Colvin, M.K., et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17:5 (2018), 445–455.
Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:1 (2010), 77–93.
Kwon, J.M., Abdel-Hamid, H.Z., Al-Zaidy, S.A., Mendell, J.R., Kennedy, A., Kinnett, K., et al. Clinical follow-up for duchenne muscular dystrophy newborn screening: a proposal. Muscle Nerve 54:2 (2016), 186–191.
Kucera, K.S., Boyea, B.L., Migliore, B., Potter, S.N., Robles, V.R., Kutsa, O., et al. Two years of newborn screening for duchenne muscular dystrophy as a part of the statewide early check research program in North Carolina. Genet Med, 26(1), 2024, 101009.
Nallamilli, B.R.R., Chaubey, A., Valencia, C.A., Stansberry, L., Behlmann, A.M., Ma, Z., et al. A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing. Hum Mutat 42:5 (2021), 626–638.
Mercuri, E., Seferian, A.M., Servais, L., Deconinck, N., Stevenson, H., Ni, X., et al. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping. NMD 33:6 (2023), 476–483.
Connolly, A.M., Florence, J.M., Cradock, M.M., Eagle, M., Flanigan, K.M., McDonald, C.M., et al. One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol 50:6 (2014), 557–563.
Gruber, D., Lloyd-Puryear, M., Armstrong, N., Scavina, M., Tavakoli, N.P., Brower, A.M., et al. Newborn screening for Duchenne muscular dystrophy-early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy. Am J Med Genet C Semin Med Genet 190:2 (2022), 197–205.
Bradley, D.M., Parsons, E.P., Clarke, A.J., Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 306:6874 (1993), 357–360.
Servais, L., Eggenspieler, D., Poleur, M., Grelet, M., Muntoni, F., Strijbos, P., et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nat Med 29:10 (2023), 2391–2392.
Parsons, E.P., Clarke, A.J., Hood, K., Lycett, E., Bradley, D.M., Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch Dis Child Fetal Neonatal editor 86:2 (2002), F91–F95.
Scheuerbrandt, G., Screening for Duchenne muscular dystrophy in Germany, 1977-2011: a personal story. Muscle Nerve 57:2 (2018), 185–188.
Colvin, M.K., Poysky, J., Kinnett, K., Damiani, M., Gibbons, M., Hoskin, J., et al. Psychosocial management of the patient with duchenne muscular dystrophy. Pediatrics 142:Suppl 2 (2018), S99–s109.
